Moderna, Inc. (MRNA) announced the dosing of the first participant in the phase III Nova 301 study, which is evaluating its investigational mRNA norovirus vaccine candidate, mRNA-1403, in the United States. The randomized, placebo-controlled phase III study will evaluate the safety, efficacy and immunogenicity of mRNA-1403 to prevent moderate-to-severe acute gastroenteritis caused by norovirus. Recruitment of participants in the pivotal Nova 301 study across the world has also begun. Shares of Moderna have ...